1-fluoro-4-[(2R)-3-methylbutan-2-yl]benzene | 1364975-40-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-fluoro-4-[(2R)-3-methylbutan-2-yl]benzene
• CAS: 1364975-40-5
• 化学式: C₁₁H₁₅F
• 分子量: 166.239
• InChiKey: PYZCQGAJIAQOEM-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-methyl-2-(4-fluorophenyl)-1-butene 在 C₃₀H₄₄CoN₃ 、 氢气 作用下， 以 苯 为溶剂， 22.0 ℃ 、405.33 kPa 条件下， 反应 24.0h， 生成 1-fluoro-4-[(2R)-3-methylbutan-2-yl]benzene 、 1-((S)-1,2-Dimethyl-propyl)-4-fluoro-benzene
  参考文献：
  名称：

  EnantiopureC₁-Symmetric Bis(imino)pyridine Cobalt Complexes for Asymmetric Alkene Hydrogenation

  摘要：

  Enantiopure C-1-symmetric bis(imino)pyridine cobalt chloride, methyl, hydride, and cyclometalated complexes have been synthesized and characterized. These complexes are active as catalysts for the enantioselective hydrogenation of geminal-disubstituted olefins.

  DOI：

  10.1021/ja300503k

文献信息

• PTERIDINONE COMPOUNDS AND USES THEREOF
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20190322673A1

  公开（公告）日：2019-10-24

  The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

  本发明提供了式I的化合物或其药学上可接受的盐，以及用于治疗细胞增殖性疾病（例如癌症）的药物组合物和使用方法。
• Azetidinone Derivatives and Methods of Use Thereof
  申请人：Aslanian G. Robert

  公开号：US20080076751A1

  公开（公告）日：2008-03-27

  The present invention relates to Azetidinone Derivatives, compositions comprising an Azetidinone Derivative and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of an Azetidinone Derivative.

  本发明涉及吲哚酮衍生物，包含吲哚酮衍生物的组合物以及治疗或预防脂质代谢紊乱、疼痛、糖尿病、血管疾病、脱髓鞘病或非酒精性脂肪肝病的方法，包括向患者投予有效量的吲哚酮衍生物。
• PYRROLOTRIAZINE KINASE INHIBITORS
  申请人：Fink E. Brian

  公开号：US20080058337A1

  公开（公告）日：2008-03-06

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB and TrkC thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

  本发明提供了I型化合物及其药学上可接受的盐。公式I的化合物抑制Trk受体的酪氨酸激酶活性，如TrkA、TrkB和TrkC，因此使它们成为抗增殖剂，用于治疗癌症和其他疾病。
• Heterobicyclic metalloprotease inhibitors
  申请人：Bluhm Harald

  公开号：US20080221092A1

  公开（公告）日：2008-09-11

  The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors.

  本发明通常涉及含有酰胺的杂双环含有药物作用的化合物，特别地，涉及含有酰胺的杂双环金属蛋白酶抑制剂。更具体地，本发明提供了一类新型的杂双环MMP-3和/或MMP-13抑制剂化合物，相对于目前已知的MMP-13和MMP-3抑制剂，这些化合物表现出更高的效力和选择性。
• VIRAL POLYMERASE INHIBITORS
  申请人：STAMMERS Timothy

  公开号：US20110230465A1

  公开（公告）日：2011-09-22

  Compounds of formula I: wherein X, R 2 , R 3 , R 5 and R 6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

  式I的化合物：其中X、R2、R3、R5和R6的定义如本文所述，可用作丙型肝炎病毒NS5B聚合酶的抑制剂。